Form 6-K — CureVac N.V.: Chief Development Officer Klaus Edvardsen will leave the Company (June 8, 2022)

Summary

A Form 6-K report of foreign private issuer filed by CureVac N.V. with the U.S. Securities and Exchange Commission for the month of June, 2022, Commission File Number 001-39446. It states that on June 8, 2022 the company issued a press release announcing that Chief Development Officer Klaus Edvardsen will leave the company on June 30, 2022. Myriam Mendila is named to the role with an appointment taking effect on February 1, 2023, and until then Ulrike Gnad-Vogt, Senior Vice President Area Head Oncology, will act as interim Chief Development Officer. The press release is Exhibit 99.1, and the information is incorporated into Form F-3, File No. 333-259613.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE
ISSUER

PURSUANT TO RULE 13a-16
OR 15d-16 OF THE

SECURITIES EXCHANGE ACT
OF 1934

For the month of June, 2022

Commission File Number: 001-39446

CureVac N.V.

( Exact Name of Registrant as Specified in Its
Charter )

Friedrich-Miescher-Strasse 15, 72076

Tübingen, Germany

+49 7071 9883 0

(Address of principal executive office)

Indicate by check mark whether the registrant files
or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F x | Form 40-F ¨

Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes ¨ | No x

Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes ¨ | No x

On June 8, 2022, CureVac
N.V. (the “Company”) issued a press release announcing that Chief Development Officer Klaus Edvardsen will leave the Company
on June 30, 2022. He plans to return home to Denmark for a new professional opportunity. CureVac is pleased to welcome Myriam Mendila
to this key role. Myriam’s appointment will take effect on February 1, 2023. Until then, Ulrike Gnad-Vogt, Senior Vice President
Area Head Oncology, will act as interim Chief Development Officer.

The information included in this Form 6-K (including Exhibit 99.1,
but excluding the statements of the Company’s Chief Executive Officer, Chief Development Officer and Chairman of the Company’s
Board of Directors contained in Exhibit 99.1 hereto) is hereby incorporated by reference into the Company’s Registration Statement
on Form F-3 (File No. 333-259613).

SIGNATURES

Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

CUREVAC N.V.
By: | /s/ Franz-Werner Haas, LLD, LLM
Chief Executive Officer

Date: June 8, 2022

EXHIBIT INDEX

EXHIBIT NO. | DESCRIPTION
99.1 | CureVac N.V. Press Release dated June 8, 2022.

File and source

File

SEC_CVAC_6-K_filed2022-06-08_0001104659-22-069318.htm

Size

13,378 bytes

SHA-256

c3b698fc8cc8943c117aac332874e1b45a8d5c5337fccbd537d543af1efb24fa

Our copy

SEC_CVAC_6-K_filed2022-06-08_0001104659-22-069318.htm

Original

www.sec.gov